Skip to main content

Table 7 Frequencies of protein expression levels between primary and metastatic tumors

From: Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors

Protein

Primary tumors

Metastatic tumors

Sign test, P value

 

0

1

2

0

1

2

 

pHER1

25

--

5

11

--

19

0.0003

pHER2

17

5

7

14

10

6

0.6072

pHER3

23

--

5

16

--

13

0.0034

Nuclear pHER3

27

--

1

15

--

14

0.0002

HER4

--

13

17

--

19

10

0.1435

Cytoplasmic pErk

10

4

15

6

12

12

1.0000

Nuclear pErk

10

3

16

6

6

18

0.4545

Cytoplasmic pAkt

3

19

8

10

5

14

0.8036

Nuclear pAkt

16

8

8

10

7

12

0.0768

  1. Category 0 = number of negative cases, category 1 = number of weak-expressing (pHER2), low-expressing (HER4) or moderate-expressing (pErk and pAkt) cases, and category 2 = number of positive (pHER1 and pHER3) or strong-expressing (pHER2, pErk and pAkt) cases. Expression of pHER1, pHER3 and nuclear pHER3 was analyzed as negative or positive, hence '--' in category 1. HER4 expression was evaluated as either low or high, hence '--' in category 0. The Sign test was used to examine for significant differences in protein expression levels between primary and metastatic tumors. Bold data represent significant values.